These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

824 related items for PubMed ID: 18336606

  • 1. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R.
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [Abstract] [Full Text] [Related]

  • 2. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ.
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [Abstract] [Full Text] [Related]

  • 3. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.
    Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL.
    Cancer; 2002 Nov 15; 95(10):2136-44. PubMed ID: 12412167
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
    Spry NA, Galvão DA, Davies R, La Bianca S, Joseph D, Davidson A, Prince R.
    BJU Int; 2009 Sep 15; 104(6):806-12. PubMed ID: 19281463
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
    Taaffe DR, Galvão DA, Spry N, Joseph D, Chambers SK, Gardiner RA, Hayne D, Cormie P, Shum DHK, Newton RU.
    BJU Int; 2019 Feb 15; 123(2):261-269. PubMed ID: 30239116
    [Abstract] [Full Text] [Related]

  • 9. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation.
    Galvão DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU.
    Prostate Cancer Prostatic Dis; 2009 Feb 15; 12(2):198-203. PubMed ID: 18852703
    [Abstract] [Full Text] [Related]

  • 10. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.
    BJU Int; 2009 Dec 15; 104(11):1637-40. PubMed ID: 19549260
    [Abstract] [Full Text] [Related]

  • 11. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.
    Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS.
    J Clin Oncol; 2004 Jul 01; 22(13):2546-53. PubMed ID: 15226323
    [Abstract] [Full Text] [Related]

  • 12. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK, Weston R, Mistry R, Parr NJ.
    BJU Int; 2009 Sep 01; 104(6):800-5. PubMed ID: 19338564
    [Abstract] [Full Text] [Related]

  • 13. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response.
    Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU.
    J Urol; 2011 Oct 01; 186(4):1291-7. PubMed ID: 21849187
    [Abstract] [Full Text] [Related]

  • 14. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
    Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.
    J Urol; 2006 May 01; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.
    Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo ME, Wells GA.
    J Clin Oncol; 2003 May 01; 21(9):1653-9. PubMed ID: 12721238
    [Abstract] [Full Text] [Related]

  • 17. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
    Kawahara T, Kobayashi T, Nishizawa K, Kobori G, Mitsumori K, Ogura K.
    Hinyokika Kiyo; 2008 Apr 01; 54(4):261-6. PubMed ID: 18516917
    [Abstract] [Full Text] [Related]

  • 18. [Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].
    Deng J, Li W, Yang L, Wang L, Zou D.
    Zhonghua Nan Ke Xue; 2004 Oct 01; 10(10):761-3. PubMed ID: 15562791
    [Abstract] [Full Text] [Related]

  • 19. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT.
    Urology; 2007 Jul 01; 70(1):122-6. PubMed ID: 17656221
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.